TS
PACB icon

Thomas Steyer’s Pacific Biosciences PACB Stock Holding History

Thomas Steyer’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9K Sell
14,200
-120,800
-89% -$176K ﹤0.01% 84
2026
Q1 		$178K Hold
135,000
– – ﹤0.01% 153
2025
Q4 		$252K Hold
135,000
– – ﹤0.01% 122
2025
Q3 		$173K Hold
135,000
– – ﹤0.01% 127
2025
Q2 		$167K Hold
135,000
– – ﹤0.01% 125
2025
Q1 		$159K Hold
135,000
– – ﹤0.01% 126
2024
Q4 		$247K Hold
135,000
– – ﹤0.01% 119
2024
Q3 		$230K Hold
135,000
– – ﹤0.01% 136
2024
Q2 		$185K Sell
135,000
-3,637,452
-96% -$7.35M ﹤0.01% 142
2024
Q1 		$14.1M Sell
3,772,452
-2,418,918
-39% -$14.2M 0.06% 88
2023
Q4 		$60.7M Sell
6,191,370
-4,032,750
-39% -$33M 0.28% 57
2023
Q3 		$85.4M Buy
10,224,120
+1,886,000
+23% +$21.6M 0.4% 45
2023
Q2 		$111M Buy
8,338,120
+1,983,000
+31% +$24.1M 0.56% 46
2023
Q1 		$73.6M Buy
6,355,120
+2,350,720
+59% +$23.4M 0.4% 52
2022
Q4 		$32.8M Buy
+4,004,400
New +$34.5M 0.19% 71
2022
Q2 		– Sell
-1,631,800
Closed -$14.8M – 323
2022
Q1 		$14.8M Sell
1,631,800
-413,688
-20% -$4.76M 0.07% 115
2021
Q4 		$41.9M Buy
2,045,488
+53,238
+3% +$1.28M 0.21% 72
2021
Q3 		$50.9M Buy
1,992,250
+1,742,250
+697% +$51.6M 0.24% 74
2021
Q2 		$8.74M Buy
+250,000
New +$7.27M 0.04% 140
2021
Q1 		– Sell
-2,100,000
Closed -$54.5M – 245
2020
Q4 		$54.5M Sell
2,100,000
-1,963,770
-48% -$33.4M 0.33% 61
2020
Q3 		$40.1M Buy
4,063,770
+1,063,770
+35% +$6.12M 0.28% 70
2020
Q2 		$10.3M Hold
3,000,000
– – 0.08% 102
2020
Q1 		$9.18M Hold
3,000,000
– – 0.08% 84
2019
Q4 		$15.4M Buy
+3,000,000
New +$15.2M 0.1% 91

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Thomas Steyer's PACB Position: Q2 2026 in Review

Thomas Steyer reduced its Pacific Biosciences (PACB) stake by 89% in Q2 2026, selling an estimated $176K and leaving 14,200 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #84.

Thomas Steyer first reported a position in PACB in Q4 2019 and has held it in 24 quarters since. The position peaked at $111M in Q2 2023. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Thomas Steyer held 14,200 shares of Pacific Biosciences worth $23.9K as of Q2 2026.
  • Thomas Steyer sold 120,800 Pacific Biosciences shares in Q2 2026, an estimated $176K.
  • Pacific Biosciences made up ﹤0.01% of Thomas Steyer's portfolio in Q2 2026, its #84 holding.
  • Thomas Steyer first reported a position in Pacific Biosciences in Q4 2019 and has held it in 24 quarters since.
  • Thomas Steyer's Pacific Biosciences position peaked at $111M in Q2 2023.
  • 222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.